Anil Puri, MD
Pulmonary Disease · Augusta, GANPI 1629166335
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 28.7% of the total. Reporting peaked in 2022 at $1,018 and has fallen 96.7% since, to $34 in 2025. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 185 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$534
- Novo Nordisk$259
- Sanofi$196
- Pfizer$188
- Lilly USA, LLC$161
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,85899%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $1,113 |
| GSK | 24 | $534 |
| Novo Nordisk | 16 | $259 |
| Sanofi | 9 | $196 |
| Pfizer | 7 | $188 |
| Lilly USA, LLC | 9 | $161 |
| Edwards Lifesciences | 1 | $150 |
| Bayer | 4 | $126 |
| Merck | 7 | $116 |
| Amgen | 7 | $112 |
| Harmony Biosciences LLC | 6 | $109 |
| Abbott | 5 | $95 |
| Dexcom, Inc. | 6 | $94 |
| Johnson & Johnson | 2 | $93 |
| Boehringer Ingelheim | 5 | $84 |
| Advanced Respiratory, Inc | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| Novartis | 3 | $47 |
| Mylan Specialty L.p. | 3 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Baxter Healthcare | 1 | $23 |
| Philips North America LLC | 1 | $23 |
| Resmed Corp | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$150
- FARXIGA$115
- AREXVY$102
How this compares
$3,880 in reported general payments places this provider in the 50th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 316 | $352,462 |
| OzempicSemaglutide | 94 | $155,012 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 147 | $137,131 |
| JardianceEmpagliflozin | 110 | $109,936 |
| FarxigaDapagliflozin Propanediol | 118 | $106,517 |
| EliquisApixaban | 94 | $92,229 |
| MounjaroTirzepatide | 50 | $68,496 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $41,741 |
| XareltoRivaroxaban | 30 | $36,168 |
| RybelsusSemaglutide | 21 | $31,823 |
| Repatha SureclickEvolocumab | 21 | $27,721 |
| JanuviaSitagliptin Phosphate | 30 | $26,608 |
| EntrestoSacubitril/Valsartan | 23 | $25,340 |
| Spiriva RespimatTiotropium Bromide | 23 | $24,082 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 62 | $17,972 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Anoro Ellipta, Shingrix | $534 | $439,583506 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,113 | $251,466288 claims |
| Novo NordiskOzempic, Rybelsus | $259 | $186,836115 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Trijardy Xr, Glyxambi | $84 | $175,880194 claims |
| PfizerEliquis | $188 | $92,22994 claims |
| Lilly USA, LLCMounjaro | $161 | $68,49650 claims |
| Johnson & JohnsonXarelto | $93 | $36,16830 claims |
| MerckJanuvia | $116 | $26,60830 claims |
| NovartisEntresto | $47 | $25,34023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Augusta
- Carmel JosephAugusta$43K
- Shaheen IslamAugusta$22K
- Varsha KulkarniAugusta$19K
- Scott PethkeAugusta$14K
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.